

# Minglei Zhuo

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8373100/minglei-zhuo-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54  
papers

1,442  
citations

17  
h-index

37  
g-index

59  
ext. papers

1,725  
ext. citations

4.5  
avg, IF

3.73  
L-index

#	Paper	IF	Citations
54	Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations. <i>BMC Cancer</i> , <b>2021</b> , 21, 1107	4.8	1
53	Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting. <i>Journal of Thoracic Disease</i> , <b>2021</b> , 13, 1813-1821	2.6	0
52	Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma-A Retrospective Analysis of a Multicenter Clinical Study. <i>Frontiers in Molecular Biosciences</i> , <b>2021</b> , 8, 639892	5.6	5
51	A phase II study of vorolanib in combination with toripalimab in patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e21053-e21053	2.2	1
50	Relationship between loss-of-function mutation of the stromal antigen 2 gene and treatment in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e20509-e20509	2.2	
49	Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 33	3.2	7
48	Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 981-994	4.4	4
47	Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage I-IIIa non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , <b>2021</b> , 13, 1799-1812	2.6	0
46	Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. <i>Cancer Cell International</i> , <b>2020</b> , 20, 590	6.4	
45	Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 729	5.3	7
44	Analysis of MET kinase domain rearrangement in NSCLC. <i>Lung Cancer</i> , <b>2020</b> , 145, 140-143	5.9	5
43	Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1149-1159	3.2	2
42	Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 626	5.3	5
41	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 892-901	12.9	34
40	Co-mutation features in treatment-naïve EGFR-mutant lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e21616-e21616	2.2	
39	A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database. <i>BMC Cancer</i> , <b>2020</b> , 20, 666	4.8	8
38	Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1137	5.3	3

37	The adverse events associated with combination immunotherapy in cancers: Challenges and chances. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2020</b> , 16, e154-e159	1.9	3
36	Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis. <i>BMC Cancer</i> , <b>2020</b> , 20, 793	4.8	6
35	Characterization of Microbiota in Cancerous Lung and the Contralateral Non-Cancerous Lung Within Lung Cancer Patients. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1584	5.3	1
34	Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 574752	5.3	3
33	Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5049-5060	12.9	31
32	Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1193-1202	3.2	4
31	Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1788-1797	3.2	5
30	Optimal first-line treatment for advanced thymic carcinoma. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 2081-2087	3.2	6
29	ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 2088-2095	3.2	14
28	Survival comparison of right and left side non-small cell lung cancer in stage I-IIIa patients: A Surveillance Epidemiology and End Results (SEER) analysis. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 459-471	3.2	8
27	Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases. <i>Cancer Research</i> , <b>2019</b> , 79, 7-20	10.1	63
26	Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 291-297	3.2	4
25	Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 1166-1173	3.2	7
24	Correlation among genetic variations of c-MET in Chinese patients with non-small cell lung cancer. <i>Oncotarget</i> , <b>2018</b> , 9, 2660-2667	3.3	8
23	The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients. <i>Cancer Biomarkers</i> , <b>2018</b> , 22, 467-476	3.8	18
22	Analysis of mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer. <i>Oncology Letters</i> , <b>2017</b> , 13, 2425-2431	2.6	11
21	Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1376-1387	8.9	29
20	Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments. <i>Thoracic Cancer</i> , <b>2017</b> , 8, 138-146	3.2	10

19	Programmed cell death-ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC). <i>Thoracic Cancer</i> , <b>2017</b> , 8, 73-79 <sup>3.2</sup>	14
18	Survival difference between Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , <b>2017</b> , 29, 553-560	3.8 10
17	Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1766-1778	8.9 35
16	A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , <b>2016</b> , 28, 12-8	3.8 1
15	Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 20810-24	3.3 63
14	Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung. <i>Thoracic Cancer</i> , <b>2015</b> , 6, 319-26	3.2 9
13	ER $\beta$ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations. <i>Scientific Reports</i> , <b>2015</b> , 5, 11392	4.9 15
12	Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation. <i>Journal of Hematology and Oncology</i> , <b>2015</b> , 8, 127	22.4 37
11	Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. <i>PLoS ONE</i> , <b>2014</b> , 9, e110780	3.7 109
10	Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors. <i>Thoracic Cancer</i> , <b>2014</b> , 5, 126-32	3.2 16
9	Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 21083-8	11.5 344
8	Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e51021	3.7 7
7	Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e54170	3.7 76
6	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3077-83	2.2 154
5	EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer. <i>Oncology</i> , <b>2012</b> , 83, 248-56	3.6 36
4	The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. <i>Thoracic Cancer</i> , <b>2012</b> , 3, 334-340	3.2 35
3	DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2012</b> , 31, 80	12.8 30
2	Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1324-30	12.9 85

- 1 EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. *Lung Cancer*, **2010**, 67, 343-7 5.9 46